» Articles » PMID: 28841180

Radiolabeled Dendrimers for Nuclear Medicine Applications

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2017 Aug 26
PMID 28841180
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Recent advances in nuclear medicine have explored nanoscale carriers for targeted delivery of various radionuclides in specific manners to improve the effect of diagnosis and therapy of diseases. Due to the unique molecular architecture allowing facile attachment of targeting ligands and radionuclides, dendrimers provide versatile platforms in this filed to build abundant multifunctional radiolabeled nanoparticles for nuclear medicine applications. This review gives special focus to recent advances in dendrimer-based nuclear medicine agents for the imaging and treatment of cancer, cardiovascular and other diseases. Radiolabeling strategies for different radionuclides and several challenges involved in clinical translation of radiolabeled dendrimers are extensively discussed.

Citing Articles

[F]-Radiolabelled Nanoplatforms: A Critical Review of Their Intrinsic Characteristics, Radiolabelling Methods, and Purification Techniques.

Deleuziere M, Benoist E, Quelven I, Gras E, Amiens C Molecules. 2024; 29(7).

PMID: 38611815 PMC: 11013168. DOI: 10.3390/molecules29071537.


Peering into the Brain's Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders.

Arjmand S, Bender D, Jakobsen S, Wegener G, Landau A Biomolecules. 2023; 13(9).

PMID: 37759805 PMC: 10526964. DOI: 10.3390/biom13091405.


Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents.

Winuprasith T, Koirala P, McClements D, Khomein P Int J Nanomedicine. 2023; 18:4449-4470.

PMID: 37555189 PMC: 10406121. DOI: 10.2147/IJN.S416737.


Nanoparticles and Radioisotopes: A Long Story in a Nutshell.

Poletto G, Evangelista L, Venturini F, Gramegna F, Seno F, Moro S Pharmaceutics. 2022; 14(10).

PMID: 36297457 PMC: 9612364. DOI: 10.3390/pharmaceutics14102024.


A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Therapeutic Isotopes.

Gholami Y, Josephson L, Akam E, Caravan P, Wilks M, Pan X Int J Nanomedicine. 2020; 15:31-47.

PMID: 32021163 PMC: 6954846. DOI: 10.2147/IJN.S227931.


References
1.
Tsuchimochi M, Hayama K, Toyama M, Sasagawa I, Tsubokawa N . Dual-modality imaging with 99mTc and fluorescent indocyanine green using surface-modified silica nanoparticles for biopsy of the sentinel lymph node: an animal study. EJNMMI Res. 2013; 3(1):33. PMC: 3639813. DOI: 10.1186/2191-219X-3-33. View

2.
Hou S, Choi J, Garcia M, Xing Y, Chen K, Chen Y . Pretargeted Positron Emission Tomography Imaging That Employs Supramolecular Nanoparticles with in Vivo Bioorthogonal Chemistry. ACS Nano. 2016; 10(1):1417-24. PMC: 4893318. DOI: 10.1021/acsnano.5b06860. View

3.
Gomes C, Abrunhosa A, Ramos P, Pauwels E . Molecular imaging with SPECT as a tool for drug development. Adv Drug Deliv Rev. 2010; 63(7):547-54. DOI: 10.1016/j.addr.2010.09.015. View

4.
McQuade P, Rowland D, Lewis J, Welch M . Positron-emitting isotopes produced on biomedical cyclotrons. Curr Med Chem. 2005; 12(7):807-18. DOI: 10.2174/0929867053507397. View

5.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View